Veru secures fda agreement to initiate phase 2 study of veru-111 to combat covid-19

Veru secures fda agreement to initiate phase 2 study of veru-111, novel microtubule depolymerization drug to combat covid-19.veru - phase 2 clinical study expected to commence in hospitalized covid-19 patients at high risk for acute respiratory distress syndrome in 2 weeks.veru inc - received fda permission to initiate a phase 2 clinical trial to assess efficacy of veru-111.veru inc - study is expected to commence in next 2 weeks..
VERU Ratings Summary
VERU Quant Ranking